In vitro and animal data suggest that hepatitis C virus (HCV) proteins might interfere with signal transducer and activator of transcription 3 (Stat3) signaling. It remains unknown whether Stat3 influences the apoptotic-proliferation balance and how this may relate to liver fibrosis progression in HCV-infected patients. We assessed Stat3 expression and DNA-binding as well as expression of its regulators protein inhibitor of activated Stat 3 (Pias3) and suppressor of cytokine signaling 3 (Socs3) in 65 HCV-infected livers at various stages of fibrosis progression. We then determined the level of expression of the proliferation markers cyclin D1 and proliferating cell nuclear antigen (PCNA) in conjunction with pro-and antiapoptotic markers Bax and Bcl-2 in the same liver samples. With the onset of fibrosis, Stat3 DNA-binding decreased and became almost undetectable in livers with bridging fibrosis or cirrhosis. Stat3 DNA-binding inversely correlated with Pias3 expression and Stat3-Pias3 interaction increased with the progression of fibrosis. Cyclin D1 and PCNA in hepatocytes decreased dramatically during fibrosis progression and levels highly correlated with Stat3 expression. In addition, an antiapoptotic profile due to upregulation of Bcl-2 principally in infiltrating inflammatory cells was observed with progressing fibrosis. In conclusion, fibrosis progression is characterized by a continuous decline in Stat3 DNA-binding activity related to overexpression and progressive interaction of Pias3-Stat3. The decrease in Stat3 activity correlated with reduced hepatocytes proliferation and a positive antiapoptotic balance in infiltrating inflammatory cells that are known mediators of cell damage in HCV.
Over the last years, evidence is accumulating in favor of a direct relationship between the hepatitis C virus (HCV) and intracellular mechanisms under the control of signal transducer and activator of transcription 3 (Stat3) molecules. In vitro data suggest that proteins of the HCV interfere with Stat3 signaling. [1] [2] [3] [4] Recent publications also underscore the increasing interest in Stat3 concerning the pathogenesis of HCV-related disease and antiviral response mechanisms. 5, 6 However, most of these studies were performed in cell culture or replicon systems that cannot easily be extrapolated to human disease. To date, clear evidence that Stat3 is implicated in the pathogenesis and progression of HCV-related liver disease in vivo in humans is still lacking. In addition, there is no clear consensus to whether the evolution of chronic liver disease towards fibrosis and ultimately to cirrhosis results from decreased hepatocytes proliferation, increased apoptosis or a combination of both phenomenon. [7] [8] [9] [10] [11] Stat3 may play a pivotal role in the progression of HCV-related liver disease as it controls intracellular signal transduction pathways of several proinflammatory cytokines and growth factors implicated in liver damage and repair mechanisms. [12] [13] [14] [15] In particular, disruption of Stat3-mediated intracellular signal transduction pathways leads to disturbed liver regeneration and repair 16, 17 and may therefore constitute a bridge between HCV infection, deficient cellular proliferation and the occurrence and progression of fibrosis. We previously reported that Stat3 activity is disturbed in human end-stage alcoholic and HCV-related cirrhosis. 18, 19 It remains, however, to be investigated whether alterations in Stat3 activity occur gradually during disease progression and are implicated in the pathogenesis of HCV-related liver disease or whether they should only be considered as a by-stander of end-stage liver disease. In addition, the potential relationship between Stat3 alterations and cell proliferation or apoptosis has not been clarified in human liver. Hepatitis C infection represents a suitable model to assess many of these open questions since intermediate stages of disease progression have been defined and liver tissue may be obtained from liver biopsies that are routinely performed during the clinical work-up of the disease. We hypothesize that fibrosis progression in HCV-induced liver disease may be related to a progressive alteration in Stat3 function that might ultimately alter the capacity of liver to regenerate and repair itself. To test this hypothesis, we assessed Stat3 expression and function in liver samples from HCV-infected patients at various stages of fibrosis progression. Changes in Stat3 were then correlated with changes in the expression of proliferation and apoptosis markers in the same liver samples. We show that a progressive protein inhibitor of activated Stat 3 (Pias3) induced reduction in Stat3 activity is likely implicated in the pathogenesis of the disease from viral infection to occurrence of fibrosis and progression towards cirrhosis in vivo in human liver samples. In addition, we present evidence that the progressive decrease of Stat3 activity is associated with a gradual reduction of hepatocytes proliferation and an increased antiapoptotic response in infiltrating lymphocytes. These observations suggest not only a mechanistic and pathogenic link between Stat3 and both phenomenons but also add new data to the hypothesis of cirrhosis development being a consequence of deficient cell proliferation.
MATERIALS AND METHODS Patients and Liver Samples
Liver tissue was obtained from patients undergoing liver biopsy for standard work-up of HCV infection. In addition, small cubes of liver tissue were removed from explanted livers of HCV patients at transplantation. Surplus tissue from size-reduced liver grafts was used as histologically normal HCV-negative liver specimens (n ¼ 6). Tissue samples were immediately frozen in liquid nitrogen and stored at À801C until use. Only surplus tissue that was not required for pathological analysis anymore was used for the study. Consequently, due to the very limited amount of tissue available from liver biopsies, the specimens were divided into two series of samples: one series was used for mRNA studies and Stat3 DNA-binding experiments and the second one was designated to immunoprecipitation and protein expression studies. As a consequence, correlations can only be established for the paired analysis of various factors in each series. Overall HCV samples from 65 patients have been used for this study. The number of HCV-positive specimens (n) used to perform the various analyses is indicated in the respective graphs and figures. All tissue samples were examined by an experienced liver pathologist and scored according to the Ludwig's scoring system. 20 Samples with high grade of portal and or lobular inflammation (P2L2, P3L1-3, P1-3L3) were discarded to minimize the impact of tissue inflammation on the expression and activity of the various factors examined in the study. Samples were matched for low portal (P) and lobular (L) inflammation scores (P1L2 or P2L1) in order to assure homogeneity and to focus on the variation of fibrosis as the principal pathological factor. According to the fibrosis score, the specimens were subdivided into three groups: no fibrosis (S1), fibrotic septas extending from the portal tracts (S2), bridging fibrosis and/or established cirrhosis (S3/4).
Preparation of Cellular Extracts
Liver homogenates were prepared as previously described. 18 Whole liver cell extracts were obtained from frozen tissues using a commercially available extract kit as indicated by the manufacturer (Active Motif, Rixensart, Belgium). Protein concentrations were determined using a BCA Protein Assay (Pierce Chemical, Rockford, IL, USA).
RNA Isolation
Total RNA was prepared from frozen liver tissue using TriPure Isolation Reagent (Roche Diagnostics, Mannheim, Germany).
Immunoblotting
Immunoblotting was performed according to standard techniques. The membranes were revealed with primary and secondary antibodies as summarized in Table 1 .
Protein expression was quantified by densitometry using the Gel Doc 2000 system and soft ware (Bio-Rad Laboratories, Nazareth, Belgium) and normalized for their respective b-actin levels (loading controls). Three identical samples were systematically loaded on each membrane in order ensure homogeneity and allow comparisons between the membranes. Membranes were stripped (Restoret Western Blot Stripping Buffer, Pierce Chemical) and reprobed whenever possible.
Immunoprecipitation
The Seize s X Protein A immunoprecipitation Kit (Pierce Chemical) was used to for immunoprecipitation studies according to the instructions of the manufacturer.
Immunohistochemistry
Immunohistochemical staining of proliferating cell nuclear antigen (PCNA) on liver slides was performed as previously described. 21 A similar procedure was used for Bcl-2 and Bax staining, except that slides were heated in a 10 mM citrate buffer pH 5.7 for 75 min for optimal antigen retrieval. Antibodies and working conditions are depicted in Table 1 .
Stat3 DNA-Binding Activity Assay
The TransAMt Stat3 transcription factor assay kit (Active Motif) was used to determine Stat3 DNA-binding activity following the instructions of the manufacturer. Reverse Transcription and Real-Time Polymerase Chain Reaction As previously reported in detail, 18 total liver RNA was reverse-transcribed and analyzed by quantitative polymerase chain reaction (PCR) (GeneAmp s 5700 Sequence Detection System and software, Applied Biosystems, Den Ijssel, Netherlands) according to standard methods and the standardized thermal profile of the system set by the manufacturer. Primers were designed using the Primer Expresst design software (Applied Biosystems) and are summarized in Table 2 .
Quantifications were obtained based on the DC T values as indicated by the manufacturer.
Statistical Analysis
Results are expressed as means7standard error of the mean (s.e.m.). Statistical differences between the groups were tested using the Student's t-test. The Spearman nonparametric test was used to examine correlations. Statistical significance was assumed for a P-value o0.05.
RESULTS

The Impact of Viral Infection on the Expression of Stat3 and Stat3 Regulators Compared to Normal HCV-Negative Livers
As a first step, we examined whether the presence of the virus does modify the expression of Stat3 and its regulators. Therefore, liver samples from HCV-infected patients without evidence of fibrosis on histology and minimal inflammation scores were compared to histological normal HCV-negative liver samples.
Viral infection elicited a fivefold decrease in Stat3 mRNA expression compared to noninfected normal livers (0.2170.03 vs 1.0370.14, Po0.001). However, total Stat3 and phospho-Stat3 protein expression were only slightly reduced in HCV-infected livers compared to normal ones ( Figure 1 ). Pias3, an inhibitor of Stat3 DNA-binding in the nucleus, 22 was weakly expressed in normal livers. Viral infection did not affect Pias3 mRNA expression compared to normal liver samples (1.2370.14 vs 1.5570.25, P ¼ NS) but slightly increased Pias3 protein levels ( Figure 1 
Fibrosis Progression in HCV-Infected Livers is Associated with an Additional Highly Significant Decline in Stat3 Function
Viral infection seems to interfere with Stat3 function in HCV-infected nonfibrotic livers as indicated by our observations above. Given the potential role of Stat3 in liver repair mechanisms, we were prompted to investigate whether the occurrence and progression of fibrosis is associated with a Stat3 and fibrosis progression in HCV P Stärkel et al preventing the transcription factor from binding to its DNA-binding site. In addition, Pias3 mRNA expression significantly correlated with Stat3 DNA-binding activity (Table 3) , which further sustains a strong relationship between Stat3 and Pias3 in HCV-infected livers progressing towards cirrhosis.
Decreased Hepatocyte Proliferation during Fibrosis Progression in HCV-Infected Livers Correlates with Reduced Stat3 Expression and Function
Stat3 is though to play an important role in eliciting hepatocyte proliferation and liver repair after injury. [12] [13] [14] [15] In addition, there is currently no clear consensus whether liver fibrosis results from an alteration in the capacity of hepatocytes to proliferate or whether apoptosis constitutes the predominant phenomenon. We therefore studied the expression of two proliferation markers, cyclin D1 and PCNA at various stages of fibrosis and correlated them with Stat3 expression. Cyclin D1 is one of the earliest markers of cell cycle entry, whereas PCNA is activated during mid-to late-G1-phase of the cell cycle. Viral infection per se did not affect cyclin D1 and PCNA expression since no significant differences were found when HCV-negative normal livers were compared to HCV-infected livers without fibrosis (not shown). However, cyclin D1 and PCNA decreased significantly (by 25 and 50%, respectively) with the onset of fibrosis. An additional reduction of cyclin D1 by more than 50% occurred in livers with bridging fibrosis or cirrhosis, whereas PCNA remained on constantly low levels throughout fibrosis progression (Figure 4a, b) . Immunohistochemical studies revealed that PCNA was principally expressed in hepatocytes in nonfibrotic livers (Figure 5a ) and occasionally in sinusoidal endothelial and Kupffer cells. The majority of the hepatocytes nuclei stained weakly to moderately positive for PCNA, whereas strong nuclear staining was only observed in a few hepatocytes. During fibrosis progression, PCNA was expressed essentially in hepatocytes and staining intensity decreased such as hardly any nuclear staining was found in livers with bridging fibrosis or cirrhosis (S3/4) (Figure 5b ). Taken together, preferential PCNA expression in hepatocytes and the reduction of total PCNA and cyclin D1 levels quantified by Western blotting suggest a progressive alteration of hepatocyte proliferation during the fibrotic process. Owing to limited amount of tissue available from liver biopsies, paired analyses could only be performed for Stat3 protein expression and the protein expression of proliferation markers. As Stat3 DNA-binding and Stat3 protein expression decreased in a similar way during fibrosis progression, we used Stat3 protein expression to examine potential correlation with protein expression of various markers assessed in the study. Interestingly, both proliferation markers signi- (Table 3) suggesting a link between downregulation of Stat3 and reduced hepatocytes proliferation during fibrosis progression.
Fibrosis Progression in HCV-Infected Livers is Associated with a Strong Antiapoptotic Profile in Infiltrating Inflammatory Cells
In order to assess the potential role of apoptosis in the process of fibrosis progression, we next studied the expression of two principal markers, Bax and Bcl-2, regulating the pro-and antiapoptotic balance. Viral infection did not affect the expression of Bax and Bcl-2 since their levels of expression were similar in HCV-negative normal livers and HCVinfected livers without fibrosis (not shown). In addition, Bax expression did not vary with the progression of fibrosis Stat3 and fibrosis progression in HCV P Stärkel et al teins interfere with Stat3 activation and signaling. 1, 3, [25] [26] [27] Our group has also shown that Stat3 activity is altered in vivo in human alcoholic and HCV end-stage liver disease. 18, 19 Although one can conclude from these observations that Stat3 activity is altered by infection with HCV, it remains to be established whether inhibition of Stat3 activity plays a role in disease progression in vivo in humans and how this alteration relates to the proliferation-apoptosis status in HCV liver samples with various levels of fibrosis. The present study shows that HCV in human liver samples in vivo, induces an alteration in Stat3 function that worsens with fibrosis progression leading to an almost complete Stat3 inhibition at the stage of cirrhosis. The progressive inhibition of Stat3 correlates significantly with a gradual increase in Pias3 expression and formation of Stat3-Pias3 protein complexes preventing the transcription factor from binding its DNAbinding site. In addition, progressive inhibition of Stat3 DNA-binding during fibrosis progression significantly cor- Stat3 and fibrosis progression in HCV P Stärkel et al relates with a reduced proliferative capacity of hepatocytes. Our findings are sustained by recent data that showed altered Stat3 activation in HCV-infected livers presumably related to reduced Stat3 expression. 28 These observations are in contradiction to HCV replicon experiments where expression of HCV proteins generally induced Stat3 expression and activity. 3, 26, 27 However, replicons are usually established in immortalized tumor cells that might behave different than differentiated hepatocytes in vivo in humans. 29 Pias3, a known inhibitor of Stat 3 DNA-binding, 22 is upregulated in HCV livers compared to normal noninfected livers and further increases during fibrosis progression. Immunoprecipitation studies show no or weak Stat3-Pias3 interaction in normal and HCV livers without fibrosis which might explain why Stat3 DNA-binding activity is preserved in normal livers and only slightly affected in nonfibrotic HCVinfected livers. In addition, a strong Stat3-Pias3 co-precipitation is found in livers with bridging fibrosis or cirrhosis suggesting that inhibition of Stat3 DNA-binding activity is closely related to an increase in Stat3-Pias3 interaction. This point is further sustained by a significant inverse correlation between Pias3 expression and Stat3 DNA-binding. A similar observation, that is, preserved Stat phosphorylation and decreased Stat DNA-binding activity, was made for Stat1-Pias1 in a transgenic mice expressing HCV proteins and in liver biopsies of HCV-infected patients. 30, 31 Several confounding factors that might have affected Stat3 activity need to be acknowledged. As Stat3 might be influenced by the inflammatory state, only liver biopsies with low inflammation scores were chosen to reduce the role of inflammatory changes as a potential confounder in our analysis. The interferon-mediated intracellular antiviral response to HCV might also influence the activity of Stat proteins. Especially, interferon-induced activation of Stat1 might increase SOCS3 levels that in turn downregulate Stat3 phosphorylation and activity. [32] [33] [34] It is, however, unlikely that this mechanism accounts for the progressive alteration in Stat3 DNA-binding activity in our study since no major changes in SOCS3 and phospho-Stat3 levels are found in HCV-infected livers at various stages of fibrosis.
To gain some insight in the functional consequences of alterations in Stat3 function on the proliferation-apoptosis balance, we next examined the expression of proliferation and apoptosis markers at different stages of liver fibrosis and correlated them with Stat3 expression. Fibrosis progression is associated with reduced cellular proliferation as indicated by a highly significant downregulation of cyclinD1 and PCNA expression. In addition, a highly significant correlation is found between both markers and Stat3 expression. Stat3 is known to play a role in hepatocytes proliferation in rodents. 17, 35 Inappropriate constitutive activation of Stat3 does also occur in numerous human cancers. 36 In a previous report, we have shown that Stat3 is mainly expressed in hepatocytes and small bile ducts in human livers. 18 Immunohistochemical data in this study reveals that PCNA is principally expressed in hepatocytes indicating that the reduction in expression of proliferation markers mainly reflects reduced hepatocytes proliferation. Given the preferential expression of Stat3 and PCNA in hepatocytes, it is tempting to link decreased hepatocytes proliferation to decreased Stat3 activity in HCV livers with progressive fibrosis. This hypothesis is in line with data obtained in HCV replicon experiments where the HCV core protein directly activated Stat3 which in turn resulted in cellular proliferation through upregulation of cyclin D. 3 In addition, Stat3 is thought to be involved in initiating intracellular antiviral pathways and defense mechanisms. 5, 6, 37 Reduced Stat3 function might therefore favor viral persistence that potentiates liver damage which, together with impaired repair mechanisms, might lead to fibrosis progression.
Surprisingly, progressive fibrosis is also associated with a positive overall antiapoptotic response. This positive antiapoptotic balance results primarily from increasing Bcl-2 levels. Stimulation of the antiapoptotic Bcl-2 signaling pathway as well as Bcl-2 overexpression have been reported at late stages of fibrosis progression in HCV-infected livers. [38] [39] [40] However, it remains uncertain whether and how Bcl-2 may be involved in promoting liver damage. In the present study, immunohistochemistry revealed that Bcl-2 is principally expressed by inflammatory cells of the portal tracts and by lymphocytes in the sinusoids. The absence of Bcl-2 in hepatocytes excludes a protective effect on hepatocytes. In addition, proapoptotic Bax does not seem to play a major regulatory role in hepatocytes or inflammatory cells for its overall expression does not change significantly and is principally restricted to proliferating cholangioles in an advanced stage of the disease. As hepatitis C is mainly an immunedriven disease without a direct cytotoxic effect of the virus, an antiapoptotic response in infiltrating inflammatory cells may favor the persistence of potentially cytotoxic lymphocytes aiming to clear infected hepatocytes and thereby increase liver damage. Together with a progressive decrease in Stat3-mediated proliferation and repair mechanisms of the remaining hepatocytes, fibrosis may occur and progress once a critical threshold keeping the system in balance has been passed.
Based on our studies and data reported in HCV replicon studies, we propose the following mechanism that may contribute, at least partially, to fibrosis progression in HCVinfected patients:
1. HCV infection induces a Pias3-mediated alteration of Stat3 activity. 2. Disturbed activation of Stat3-dependent intracellular signaling cascades leads to a reduced proliferation capacity of hepatocytes and may also alter the initiation of intracellular antiviral defense pathways. 3. A progressive Bcl-2-dependent switch towards an antiapoptotic profile in infiltrating inflammatory cells enhances survival of potentially cytotoxic cells that in turn aggravate liver damage.
